[Other therapeutic strategies]
☆ Watchresearch · published 2016-03-01 · by Allaïli N, Aouizerate B, Bation R, Bellivier F, Bennabi D, Bougerol T, Bubrovszky M, Camus V, Charpeaud T, Courtet P, Courvoisier P, d'Amato T, Doumy O, El-Hage W, Garnier M, Haesebaert F, Haffen E, Holtzmann J, Lançon C, Leboyer M, Llorca PM, Moliere F, Nieto I, Richieri R, Saba G, Vaiva G
Presse medicale (Paris, France : 1983) · 2016 Mar
Abstract
Non-selective and irreversible MAOI have become as third or fourth-line strategy for the management of treatment-resistant depression. Non-selective and irreversible MAOI requires careful monitoring of drug interactions and dietary restrictions. Nutritional supplements such as omega-3 have been found to produce beneficial effects in the management of treatment-resistant depression when administered in combination with the ongoing antidepressant treatment. The glutamate antagonist ketamine has been found to produce beneficial effects in the management of treatment-resistant depression while administered alone. Dopamine and/or norepinephrine agonists, such as methylphenidate, modafinil or pramipexole, have been found to produce beneficial effects in the management of treatment-resistant depression when administered in combination with the ongoing antidepressant treatment.
Ratings (0): Breadth — · Depth — · Enjoyment — · Usefulness —
Neurotransmitters
Stimuli
Community
Log in to rate and share your notes.
No contributions yet.